FernandoCFervenzaMD

PubMed

• 1 citations
  Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis.
  Sean J Barbour, Rosanna Coppo, Lee Er, Evangeline Pillebout, Maria Luisa Russo, Charles E Alpers, Agnes B Fogo, Franco Ferrario, J Charles Jennette, Ian S D Roberts, H...> ;Clinical Journal of the American Society of Nephrology. 2024 Apr 1
• Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
  Benjamin Madden, Raman Deep Singh, Mark Haas, Lilian M P Palma, Alok Sharma, Maria J Vargas, LouAnn Gross, Vivian Negron, Torell Nate, M Cristine Charlesworth, Jason D...> ;Kidney International. 2024 Mar 4
• Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes.
  Yandian, F., Caravaca-Fontán, F., Herrera Hernandez, L., Soler, M., Sethi, S., Fervenza, F.> ;Kidney International Reports. 2024 Feb 1
• Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO.
  Trimarchi, H., Coppo, R., Fervenza, F.> ;Journal of Nephrology. 2024 Jan 18
• 1 citations
  Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy.
  Vaughan, L., Miao, J., Duriseti, P., Radhakrishnan, Y., Fervenza, F., Zand, L.> ;Kidney International Reports. 2024 Jan 1
• 2 citations
  Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.
  Coppo, R., Zand, L., Fervenza, F.> ;Clinical Kidney Journal. 2023 Dec 1
• 1 citations
  Monoclonal Gammopathy and Its Association with Progression to Kidney Failure and Mortality in Patients with CKD.
  Janina Paula T Sy-Go, Simon Moubarak, Lisa E Vaughan, Nattawat Klomjit, Jason K Viehman, Ladan Zand, F C Fervenza> ;Clinical Journal of the American Society of Nephrology. 2024 Mar 1
• 2 citations
  Membranous nephropathy treatment standard.
  Yeshwanter Radhakrishnan, Ladan Zand, Sanjeev Sethi, Fernando C Fervenza> ;Nephrology, Dialysis, Transplantation. 2024 Feb 28
• Membranous nephropathy-diagnosis and identification of target antigens.
  Sanjeev Sethi, Fernando C Fervenza> ;Nephrology, Dialysis, Transplantation. 2024 Mar 27
• 2 citations
  Treatment of IgA Nephropathy: A Rapidly Evolving Field.
  Khalil El Karoui, Fernando C Fervenza, An S De Vriese> ;Journal of the American Society of Nephrology. 2024 Jan 1
• 3 citations
  Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification.
  Sanjeev Sethi, Laurence H Beck Jr, Richard J Glassock, Mark Haas, An S De Vriese, Tiffany N Caza, Elion Hoxha, Gérard Lambeau, Nicola M Tomas, Benjamin Madden, Hanna D...> ;Mayo Clinic Proceedings. 2023 Nov 1
• 7 citations
  Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
  Sanjeev Sethi, Laurence H Beck Jr, Richard J Glassock, Mark Haas, An S De Vriese, Tiffany N Caza, Elion Hoxha, Gérard Lambeau, Nicola M Tomas, Benjamin Madden, Hanna D...> ;Kidney International. 2023 Dec 1
• 1 citations
  Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy.
  Ladan Zand, Fernando C Fervenza> ;Clinical Kidney Journal. 2023 Sep 1
• 2 citations
  Future landscape for the management of membranous nephropathy.
  Fernando Caravaca-Fontán, Federico Yandian, Fernando C Fervenza> ;Clinical Kidney Journal. 2023 Aug 1
• 1 citations
  Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
  Sean J Barbour, Fernando C Fervenza, Dilshani Induruwage, Paul E Brenchley, Brad Rovin, Michelle A Hladunewich, Heather N Reich, Richard Lafayette, Nabeel Aslam, Geral...> ;Clinical Journal of the American Society of Nephrology. 2023 Oct 1
• 1 citations
  Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis.
  Amit Sethi, Joseph Grande, Ulrich Specks, Fernando C Fervenza> ;Clinical Kidney Journal. 2023 Jul 1
• Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD).
  Filippo Pinto E Vairo, Jennifer L Kemppainen, Carolyn R Rohrer Vitek, Denise A Whalen, Kayla J Kolbert, Kaitlin J Sikkink, Sarah A Kroc, Teresa Kruisselbrink, Gabriell...> ;Journal of Translational Medicine. 2023 Jun 23
• 4 citations
  Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy.
  Dalia Zubidat, Benjamin Madden, Satoru Kudose, Samih H Nasr, Luca Nardelli, Fernando C Fervenza, Sanjeev Sethi> ;Kidney International Reports. 2023 Jun 1
• 4 citations
  Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recom...
  Marta Casal Moura, Philipp Gauckler, Hans-Joachim Anders, Annette Bruchfeld, Gema M Fernandez-Juarez, Jürgen Floege, Eleni Frangou, Dimitrios Goumenos, Marten Segelmar...> ;Nephrology, Dialysis, Transplantation. 2023 Oct 31
• 5 citations
  Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use.
  Sanjeev Sethi, Marta Casal Moura, Benjamin Madden, Hanna Debiec, Samih H Nasr, Christopher P Larsen, LouAnn Gross, Vivian Negron, Raman Deep Singh, Karl A Nath, Aaron ...> ;Kidney International. 2023 Aug 1
• 3 citations
  Proteomic Analysis of Complement Proteins in Glomerular Diseases.
  Sanjeev Sethi, Lilian Monteiro P Palma, Jason D Theis, Fernando C Fervenza> ;Kidney International Reports. 2023 Apr 1
• Thyroid disease, Hypertension and Pregnancy: The need for balance illustrated in 2 cases.
  Círia Sousa, Vesna D Garovic, Marius Stan, Fernando C Fervenza, Andrea Kattah> ;American Journal of Hypertension. 2023 Mar 30
• 1 citations
  Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
  Hiddo J L Heerspink, Lesley A Inker, Hocine Tighiouart, Willem H Collier, Benjamin Haaland, Jiyu Luo, Gerald B Appel, Tak Mao Chan, Raymond O Estacio, Fernando Fervenz...> ;Journal of the American Society of Nephrology. 2023 Jun 1
• Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism.
  Marta Casal Moura, Zuoming Deng, Stephen R Brooks, Wei Tew, Fernando C Fervenza, Cees G M Kallenberg, Carol A Langford, Peter A Merkel, Paul A Monach, Philip Seo, Robe...> ;RMD Open. 2023 Mar 1
• 3 citations
  PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations.
  Marta Casal Moura, Cynthia S Crowson, Ulrich Specks, Kenneth J Warrington, Ladan Zand, Sanjeev Sethi, Fernando C Fervenza> ;Clinical Kidney Journal. 2023 Mar 1
• Join now to see all

Journal Articles

• CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report  
  Fernando C Fervenza, Karl A Nath, American Journal of Kidney Diseases
• Congophilic Fibrillary Glomerulonephritis: A Case Series  
  Stephen B Erickson, Fernando C Fervenza, Nelson Leung, American Journal of Kidney Diseases
• The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study  
  Musab S Hommos, Fernando C Fervenza, Mariam P Alexander, Mayo Clinic Proceedings
• Rituximab for the Treatment of Relapses in ANCA-Associated Vasculitis  
  Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villareal M, Jepson B..., Arthritis Rheumatol, 7/21/2014
• Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis  
  Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Am J Kidney Dis, 7/1/2014
• Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS)  
  Sethi S, Fervenza FC, Semin Thromb Hemost, 5/5/2014
• Nephrotic Syndrome Redux: A Clinical Commentary  
  Glassock RJ, Fervenza FC, Hebert L, Cameron JS, Nephrol Dial Transplant, 4/10/2014
• Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?  
  Zand L, Fervenza FC, Nephrol Dial Transplant, 4/10/2014
• A Pilot Study to Determine the Dose and Effectiveness of HPActhar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy  
  Hladunewich MA, Cattran DC, Beck LH, Sethi S, Leung N, Reich H, Fervenza FC, Nephrol Dial Transplant, 4/8/2014
• Focal Segmental Glomerulosclerosis: Towards a better understanding for the practicing nephrologist  
  Sanjeev S, Glassock R, Fervenza FC, Nephrol Dial Transplant, 3/2/2014
• Treatment of ANCA Vasculitis: New Therapies and a Look at Old Entities  
  Zand L, Specks U, Sethi S, Fervenza FC, Adv Chronic Kidney Dis, 3/1/2014
• Nephrology Quiz and Questionnaire 2013  
  Fervenza FC, Palmer B, Mehrota R, Brennan P, Choi M, Perazella M, Clin J Am Soc Nephrol, 2/27/2014
• Membranoproliferative Glomerulonephritis associated with Autoimmune Diseases  
  Zand L, Fervenza FC, Nasr SH, Sethi S, J Nephrol, 2/6/2014
• Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis  
  Clain JM, Cartin-Ceba R, Fervenza FC, Specks U, Therapeutic Adv in Musc Dis, 1/1/2014
• Clinical Findings, Pathology and Outcomes of C3 Glomerulonephritis following Kidney Transplantation  
  Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Smith RJH, Sethi S, J Am Soc Nephrol, 12/19/2013
• C3 glomerulopathy: consensus report  
  Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi..., Kidney Int, 10/30/2013
• Histologic classification of glomerular diseases: practical consequences for the clinician  
  Hass M, Fervenza FC, Ristaldi MP, Kidney Int, 10/2/2013
• Frequently-Relapsing/Steroid-Dependent minimal change disease: is rituximab the answer?  
  Fervenza FC, Sethi S, Nephrol Dial Transplant, 9/11/2013
• Treatment of idiopathic membranous nephropathy  
  Hofstra JM, Fervenza FC, Wetzels JFM, Nat Rev Nephrol, 8/1/2013
• Maintenance of Rituximab-induced Remissions in ANCA-Associated Vasculitis  
  Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair W, Fessler B, Ding L, Webber L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D..., New Engl J Med, 8/1/2013
• Attending Rounds: A patient with nephrotic-range proteinuria and focal global sclerosis on kidney biopsy  
  Fervenza FC, Clin J Am Soc Neph, 7/25/2013
• "Clinical Outcomes of Remission Induction Therapy for Severe ANCA-Associated Vasculitis"  
  Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, KallenbergCGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle ..., Arthritis Rheum, 6/10/2013
• Serum Soluble-Urokinase Receptor (suPAR) is Elevated in Kidney Transplant Candidates with Varied Causes of ESRD: Urinary suPAR Merits Further Study  
  Palacios CRF, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H, Transplantation, 6/3/2013
• C3 Glomerulonephritis associated with Monoclonal Gammopathy  
  Zand L, Fervenza FC, Smith RJH, Zhang Y, Kattah A, Sethi S, Am J Kidney Dis, 4/25/2013
• Nephrology Quiz and Questionnaire 2012  
  Fervenza FC, Palmer B, Mehrota R, Brennan P, Bleyer A, Glassock R, Clin J Am Soc Nephrol, 3/28/2013
• Join now to see all

Books/Book Chapters

• Core concepts in parenchymal kidney disease. 
  Chapter: Preface. 
  Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014
• Core concepts in parenchymal kidney disease 
  Chapter: Membranous nephropathy. 
  Page 51 - 75Fervenza FC, Passerini P, Sethi S, Ponticelli CEditors: Fervenza FC; et al.Springer, New York, NY2014
• Core concepts in parenchymal kidney disease 
  Chapter: Preface 
  Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014
• National Kidney Foundation's Primer on Kidney Diseases 
  Chapter: Membranous nephropathy. 
  Page 176 - 184Cattran DC, Fervenza FCEditors: Gilbert SJ; et al.Elsevier/Saunders, Philadelphia, PAEdition Sixt,2014
• Core Concepts in Parenchymal Kidney Disease. 
  Chapter: Membranous nephropathy. 
  Page 51 - 75Fervenza FC, Passerini P, Sethi S, Ponticelli CEditors: Fervenza FC, Passerini P, Sethi S, Ponticelli C.Springer, New York, NY2014
• Core Concepts in Parenchymal Kidney Disease. 
  Chapter: Membranoproliferative glomerulonephritis. 
  Page 77 - 85Sethi S, Fervenza FCEditors: Fervenza FC, Passerini P, Sethi S, Ponticelli C.Springer, New York, NY2014
• Primer on Kidney Disease 
  Chapter: Membranous nephropathy. 
  Fervenza FC, Cattran DCElsevierEdition 6th,2013
• Mayo Clinic Internal Medicine Board Review 
  Chapter: Acute kidney injury, glomerular disease, and tubulointerstitial disease. 
  Page 551 - 566Norby SM, Kashani KB, Fervenza FCEditors: Ficalora RD; et al.Mayo Clinic Scientific Press, Rochester2013
• Nephrology Secrets 
  Chapter: Membranous nephropathy. 
  Irazabal MV, Eirin A, Fervenza FCEditors: EV Lerma and AR Nissenson.Elsevier, Philadelphia, PAEdition 3rd,2012
• Mayo Clinic Internal Medicine Board Review 
  Chapter: Evaluation of kidney function, glomerular disease, and tubulointerstitial disease. 
  Page 613 - 627Fervenza FCEditors: Ghosh AK; et al.Mayo Clinic Scientific Press, RochesterEdition 9th,2010
• Current diagnosis & treatment, nephrology & hypertension 
  Chapter: Membranous nephropathy. 
  Page 229 - 241Fervenza FC, Cattran DCEditors: Lerma EV, Berns JS, Nissenson AR.McGraw-Hill Medical, New York, NY2009
• Current Diagnosis and Treatment in Nephrology and Hypertension 
  Chapter: Membranous nephropathy. 
  Page 229 - 241Fervenza FC, Cattran DCEditors: Lerma EV, Berns JS, Nissenson AR.McGraw-Hill Medical, New York, NY2009
• Evidence-based Nephrology 
  Chapter: Membranous nephropathy. 
  Page 158 - 169Fervenza FC, Cattran DCEditors: Molony DA, Craig JC.Hoboken: Wiley-Blackwell, Oxford2009
• Mayo Clinic internal medicine: concise textbook 
  Chapter: Nephrology. 
  Page 569 - 611Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM, Ghosh AK.Mayo Clinic Scientific Press, Rochester2008
• Mayo Clinic Internal Medicine 
  Chapter: Nephrology 
  Page 569 - 611Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM, Ghosh AK.Mayo Clinic Scientific Press, Rochester2008
• Internal Medicine Review 
  Chapter: Glomerular and Tubulo-interstitial diseases. 
  Page 691 - 705Fervenza FC, Schwab TREditors: Ghosh AK.Mayo Clinic Scientific Press2008
• Mayo Clinic Internal Medicine Review 
  Chapter: Nephrology. 
  Page 647 - 698Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM.Mayo Clinic Scientific Press, RochesterEdition 7th,2007
• Nefrologia no consultorio 
  Chapter: Membranous Nephropathy. 
  D. D'Avila and D. CattranEditors: Elvino Barros and Luis F. Goncalves.Artmed Editora S.A. Porto Alegre, RS, Brasil2007
• Mayo Clinic Medical Manual 
  Chapter: Hematuria. 
  Fervenza FC, Oxentenko AEditors: Guilherme H. M. Olivera, Gillian C. Nesbitt, Joseph G. Murphy.Taylor and Francis, MCS Press2006
• Mayo Clinic Medical Manual 
  Chapter: Hematuria 
  Fervenza FC, Oxentenko AEditors: Guilherme H. M. Olivera, Gillian C. Nesbitt, Joseph G. Murphy.Taylor and Francis, MCS Press2006
• Mayo Clinic Internal Medicine Review, 2006-2007 
  Chapter: Nephrology 
  Page 647 - 698Fervenza FC, Schwab TR, Williams AW, Albright RC Jr, Erickson SBEditors: Habermann TM.Mayo Clinic Scientific Press, RochesterEdition 7th,2006
• Current Diagnosis and Treatment in Nephrology and Hypertension 
  Chapter: Membranous Nephropathy 
  Fervenza FC, Cattran DCEditors: Edgar V. Lerma,MD, Allen R. Nissenson, M.D and Jeffrey S. Berns, MD.Lange Current Series2005
• Colour Atlas of Renal Medicine 
  Fervenza FC, JP Grande, J Pattison, B Hartley, and D GoldsmithThieme, New York, NY2004
• Mayo Clinic Internal Medicine Board Review Book 
  Chapter: Nephrology- Part I 
  Fernando Custodio Fervenza, MDEditors: T.H. Habermann.Lippincott Williams & Wilkins2004
• Colour Atlas of Renal Medicine 
  F.C. Fervenza, JP Grande, J Pattison, B Hartley, and D GoldsmithThieme, New York, NY2004
• Join now to see all

Abstracts/Posters

• "Urinary Soluble Urokinase Receptor (suPAR) is Not Elevated in Membranous Nephropathy (MN) and Does Not Correlate with Proteinuria"
  F.C. Fervenza, ASN, Philadelphia, 1/1/2014
• "C3 Glomerulonephritis Associated With Autoimmune Disorders: A Case Series".
  F.C. Fervenza, ASN, Philadelphia, 1/1/2014
• "Impact of weight loss before renal transplantation in obese patients: risk of early mortality.
  F.C. Fervenza, ASN, Philadelphia, 1/1/2014
• C4d as a marker for Immune Complex-Mediated Glomerulonephritis versus C3 glomerulopathy.
  F.C. Fervenza, ASN, Philadelphia, 1/1/2014
• IgD Heavy Chain Deposition Disease: Detection by Laser Microdissection and Mass Spectrometry.
  F.C. Fervenza, ASN, Philadelphia, 1/1/2014
• Laser Microdissection and Mass Spectrometry of ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis Shows Accumulation of Components of the Alternative and Termina...
  Sanjeev Sethi, MD, PhD, Julie A. Vrana, PhD, Ladan Zand, MD, Jason David Theis, Samih H. Nasr, MD, Fernando C. Fervenza, MD, PhD, FASN, ASN, Atlanta, 1/1/2013
• IgA Nephropathy with ANCA seropisitivity: A case series.
  Angela K. Muriithi, Lynn D. Cornell, Fernando C. Fervenza, Mary E. Fidler, Sanjeev Sethi, Samih H. Nasr, ASN, Atlanta, 1/1/2013
• Recurrent C3 glomerulonephritis: clinicopathological findings and outcomes.
  Ladan Zand, Elizabeth C. Lorenz, Fernando G. Cosio, Fernando C. Fervenza, Samih H. Nasr1, Richard J. Smith and Sanjeev Sethi, ASN, Atlanta, 1/1/2013
• Nephrotic Syndrome Study Network Baseline Characteristics.
  Gipson D, Troost J, Song P, Holzman LB, Sedor J, Cattran D, Fervenza F, Fornoni A, Kopp, J, Gadegbeku C, Adler S, Trachtman H, Nachman P, Neu A, Sethna C, Kaskel F, Ne..., ASN, Atlanta, 1/1/2013
• The Prevalence of Circulating Monoclonal Protein in Proliferative Nephropathies with Monoclonal Deposits.
  Gauri Bhutani, Fernando C. Fervenza, Sanjeev Sethi, Samih H. Nasr and Nelson Leung, ASN, Atlanta, 1/1/2013
• A Randomized, placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephr...
  F.C. Fervenza, E.T. Casey, J. J. Dillon, S. B. Erickson, M.C. Hogan, ASN, Atlanta, 1/1/2013
• A multicenter, randomized, prospective, open-label trial of rituximab in the treatment of progressive IgA Nephropathy.
  F.C. Fervenza, J.J. Dillon, S.B. Erickson, E.L. Greene, M.C. Hogan, ASN, Atlanta, 1/1/2013
• A randomized controlled trial of rituximab (RTX) versus cyclosporine (CSA) in the treatment of idiopathic membranous nephropathy (IMN).
  F.C. Fervenza, N. Aslam, L. Thomas, and D.C. Cattran for the investigators of the MENTOR, ASN, Atlanta, 1/1/2013
• Laser Microdissection and Mass Spectrometry of ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis Shows Accumulation of Components of the Alternative and Termina...
  Sanjeev Sethi, MD, PhD, Julie A. Vrana, PhD, Ladan Zand, MD, Jason David Theis, Samih H. Nasr, MD, Fernando C. Fervenza, MD, PhD, FASN, ASN, Atlanta, 1/1/2013
• The Efficacy of Rituximab vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE TRIAL.
  Geetha D, Fervenza FC for the RAVE-ITN Research Group, ASN, San Diego, 11/3/2012
• A Pilot Study to Determine the Dose and Effectiveness of H.P.Acthar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy.
  Fervenza FC, Cattran D, Beck LH, Reich H, Sethi S, Hladunewich MA, ASN, San Diego, 11/3/2012
• Do anti-phospholipiase A2 receptor antibodies predict recurrence of membranous nephropathy after transplantation?
  Ayalon R, Beck LH, Fervenza FC, Cosio FG, Brennan DC, Salant DJ, ASN, San Diego, 11/2/2012
• The efficacy of rituximab vs cyclophosphamide for treatment of renal disease in anca-associated vasculitis: the rave trial Geetha D, Fervenza FC for the rave-itn resea...
  Geetha D, Fervenza F, Arthritis Rheum, ACR/ARHP Annual Meeting, Washington, DC, 10/1/2012
• Predictive value of selected markers of inflammation and platelet activation for complete remission in ANCA-associated vasculitis.
  Tomasson G, Monach PA, Tanriverdi K, Specks U, Stone JH, Ding LN, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Phippard DJ, Seo P, Spiera RF, St Clair EW, Tcha..., Arthritis Rheum, ACR/ARHP Annual Meeting, Washington, DC, 10/1/2012
• Treatment of membranous nephropathy with adrenocorticotropic hormone (acth) gel: correlation of anti-pla2r and disease activity.
  Beck LH, Fervenza FC, Bomback AS, Ayalon R, Irazabal MV, Eirin A, Cattran DC, Appel GB, Salant DJ, Nephrol Dial Transplant, 5/1/2012
• Lowand high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
  Irazabal MV, Eirin A, Lieske JC, Beck LH, Dillon JJ, Nachman PH, Sethi S, Erickson SB, Cattran DC, Fervenza FC, Nephrol Dial Transplant, 5/1/2012
• C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up.
  Sethi S, Fervenza FC, Vrana JA, Nasr SH, Zhang Y, Smith RJH, Lab Invest, 2/1/2012
• C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up.
  Sethi S, Fervenza FC, Vrana JA, Zhang Y, Nasr S, Smith RJ, Modern Pathology, 1/1/2012
• Laser microdissection and proteomic analysis of amyloidosis, fibrillary and immunotactoid glomerulonephritis.
  Sethi S, Vrana JA, Theis JD, Sethi A, Nasr SH, Cornell LD, Leung N, Fervenza FC, ASN, San Diego, 1/1/2012
• Persistent' Post-Infectious Glomerulonephritis is associated with Abnormalities in the Alternative Pathway of Complement.
  Sethi S, Fervenza FC, Zand L, Zhang Y, Nasr SH, Smith RJ, ASN, San Diego, 1/1/2012
• Join now to see all

Lectures

• "B-cell depletion in nephrotic syndrome" 
  San Francisco, CA - 7/18/2014
• "Clinical presentation and treatment considerations in complement-mediated glomerular diseases" 
  National University of Ireland, Galway - 6/14/2014
• "Membranous Nephropathy New Insights Regarding Diagnosis And Treatment" 
  University of Iowa, Iowa City - 6/4/2014
• "Treatment of Membranous Nephropathy" 
  Santiago, Chile - 5/5/2014
• "Remission-induction in ANCA-associated vasculitis-A Paradigm Shift" 
  Nice, France - 3/27/2014
• "Complement-mediated renal diseases: clinical aspects, laboratory evaluation, and treatment considerations" 
  Belgium - 3/19/2014
• "Complement-mediated renal diseases: clinical aspects, laboratory evaluation, and treatment considerations." 
  Brugge, Belgium - 3/19/2014
• "ANCA vasculitis" 
  Santo Domingo, Dominican Republic - 2/27/2014
• "Membranoproliferative glomerulonephritis" 
  Santo Domingo, Dominican Republic - 2/27/2014
• "C3 Nephropathy" 
  Italy - 1/30/2014
• "Rituximab associated with mycophenolate: the LUNAR trial experience" 
  Istanbul, Turkey - 5/18/2013
• "Anti CD20: emerging treatment strategies of immune-mediated glomerular disease" 
  Istanbul, Turkey - 5/18/2013
• "Persistent post-infectious glomerulonephritis: does it exist?" 
  Istanbul, Turkey - 5/18/2013
• "Persistent post-infectious GN: does it exist?" 
  Sardinia, Italy - 4/30/2013
• "Treatment of ANCA associated vasculitis". 
  North Shore University Hospital, New York, NY - 4/27/2013
• "Possible therapeutic strategies based on pathophysiological mechanisms in Membranous Nephropathy" 
  Turin - 1/17/2013
• The Efficacy of Rituximab vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE TRIAL 
  San Diego - 11/3/2012
• A Pilot Study to Determine the Dose and Effectiveness of H.P.Acthar® Gel in Subjects Nephrotic Syndrome due to Idiopathic Membranous Nephropathy. 
  San Diego - 11/3/2012
• Do anti-phospholipiase A2 receptor antibodies predict recurrence of membranous nephropathy after transplantation? 
  San Diego - 11/2/2012
• "The Use of Biologics in Clinical Nephrology" 
  Turin, Italy - 1/19/2012
• "Idiopathic membranous nephropathy-biomarker approach". 
  San Diego, CA - 12/14/2011
• "Idiopathic membranous nephropathy-biomarker approach" 
  San Diego, CA - 12/14/2011
• "MPGN-a proposal to a new classification" 
  Yazd - 11/21/2011
• "ANCA vasculitis-treatment" 
  Yazd - 11/21/2011
• "B-cell targeted therapy in Membranous Nephropathy." 
  Yazd - 11/21/2011
• Join now to see all

Other

• The Authors Reply 
  Fernando Fervenza, MD, Kidney International
  https://www.doximity.com/articles/0d06e5eb-70ad-4a29-8688-037c2b736df2
  UpToDate, Wolters Kluwer Health - 2012-09-17
• Emerging Indications for the use of Rituximab in Glomerular Disease. 
  Kattah AG, Fervenza FC, NephSAP Volume 11, Number 3
  1/1/2012
• Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis 
  Fervenza FC, Sethi S
  http://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoprolifer
  UpToDate, Wolters Kluwer Health - 2012-09-12